{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:22:58Z","timestamp":1793128978364,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X502777\/1"],"award-info":[{"award-number":["MR\/X502777\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X502777\/1"],"award-info":[{"award-number":["MR\/X502777\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X502777\/1"],"award-info":[{"award-number":["MR\/X502777\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health, Kuwait"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BMX tyrosine kinase has emerged as a novel drug target, the inhibition of which simultaneously decreases proliferative signaling and increases cell death. BMX expression is upregulated in numerous cancers and causes acquired resistance to chemotherapeutic drugs. In addition to being responsive to multiple signaling pathways involved in regulating proliferation, migration, and cell survival, BMX is also a direct and potent negative regulator of BAK that mediates apoptotic resistance. Knockdown of BMX in cancer cells dramatically potentiates BAK activation following DNA damage, rendering cells hypersensitive to killing by otherwise sub-lethal doses of drug irrespective of the mode of drug action. This study aimed to determine whether existing BMX inhibitors could increase cell killing when used in combination with chemotherapeutic agents. We now show this sensitization can be phenocopied using small molecules BMX inhibitors, confirming inhibition of regulators upstream of the apoptotic machinery is a novel strategy to modulate cell death and improve the efficacy of existing chemotherapeutic agents. Analysis of the binding of existing BMX inhibitors BMX-IN-1 and CHMFL-BMX-078 to the BMX kinase domain reveals these molecules\u2019 potential limitations, including the high cross-reactivity with other members of the TEC kinase family. This study serves as proof-of-principle for this therapeutic strategy but also highlights the urgent need for more specific molecules to inhibit BMX kinase activity.<\/jats:p>","DOI":"10.1038\/s41419-025-08131-9","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:07:17Z","timestamp":1762787237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of tyrosine kinase BMX increases cell death in response to existing chemotherapeutic agents overcoming apoptotic resistance in cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2570-6132","authenticated-orcid":false,"given":"Dalal","family":"Morad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0399-6363","authenticated-orcid":false,"given":"Sam","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-188X","authenticated-orcid":false,"given":"Chitra","family":"Seewooruthun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-6837","authenticated-orcid":false,"given":"Joanna L.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"8131_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8131_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/0008-5472.CAN-14-1340","volume":"75","author":"JL Fox","year":"2015","unstructured":"Fox JL, Storey A. BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. Cancer Res. 2015;75:1345\u201355.","journal-title":"Cancer Res"},{"key":"8131_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1747-0285.2011.01230.x","volume":"78","author":"J Muckelbauer","year":"2011","unstructured":"Muckelbauer J, Sack JS, Ahmed N, Burke J, Chang CY, Gao M, et al. X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase. Chem Biol Drug Des. 2011;78:739\u201348.","journal-title":"Chem Biol Drug Des"},{"key":"8131_CR4","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/0008-5472.CAN-17-3615","volume":"78","author":"S Chen","year":"2018","unstructured":"Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, et al. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018;78:5203\u201315.","journal-title":"Cancer Res"},{"key":"8131_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/08830185.2012.663838","volume":"31","author":"B Cenni","year":"2012","unstructured":"Cenni B, Gutmann S, Gottar-Guillier M. BMX and its role in inflammation, cardiovascular disease, and cancer. Int Rev Immunol. 2012;31:166\u201373.","journal-title":"Int Rev Immunol"},{"key":"8131_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1359-6101(99)00019-2","volume":"10","author":"H Mano","year":"1999","unstructured":"Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev. 1999;10:267\u201380.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8131_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/sji.12069","volume":"78","author":"L Vargas","year":"2013","unstructured":"Vargas L, Hamasy A, Nore BF, Smith CI. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol. 2013;78:130\u20139.","journal-title":"Scand J Immunol"},{"key":"8131_CR8","doi-asserted-by":"publisher","first-page":"668996","DOI":"10.3389\/fcell.2021.668996","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang X, Kokabee L, Kokabee M, Conklin DS. Bruton\u2019s Tyrosine Kinase and Its Isoforms in Cancer. Front Cell Dev Biol. 2021;9:668996.","journal-title":"Front Cell Dev Biol"},{"key":"8131_CR9","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"C Tam","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8:2300\u201309.","journal-title":"Blood Adv"},{"key":"8131_CR10","doi-asserted-by":"publisher","first-page":"102842","DOI":"10.1016\/j.isci.2021.102842","volume":"24","author":"S Weeks","year":"2021","unstructured":"Weeks S, Harris R, Karimi M. Targeting ITK signaling for T cell-mediated diseases. iScience. 2021;24:102842.","journal-title":"iScience"},{"key":"8131_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12282-019-01024-8","volume":"27","author":"K Li","year":"2020","unstructured":"Li K, Pan WT, Ma YB, Xu XL, Gao Y, He YQ, et al. BMX activates Wnt\/\u03b2-catenin signaling pathway to promote cell proliferation and migration in breast cancer. Breast Cancer. 2020;27:363\u201371.","journal-title":"Breast Cancer"},{"key":"8131_CR12","doi-asserted-by":"publisher","first-page":"22757","DOI":"10.1074\/jbc.M116.737387","volume":"291","author":"MA Eldeeb","year":"2016","unstructured":"Eldeeb MA, Fahlman RP. Phosphorylation Impacts N-end Rule Degradation of the Proteolytically Activated Form of BMX Kinase. J Biol Chem. 2016;291:22757\u201368.","journal-title":"J Biol Chem"},{"key":"8131_CR13","doi-asserted-by":"publisher","first-page":"ra40","DOI":"10.1126\/scisignal.2003936","volume":"6","author":"S Chen","year":"2013","unstructured":"Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, et al. Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal. 2013;6:ra40.","journal-title":"Sci Signal"},{"key":"8131_CR14","doi-asserted-by":"publisher","first-page":"50181","DOI":"10.1074\/jbc.M409108200","volume":"279","author":"T Jiang","year":"2004","unstructured":"Jiang T, Guo Z, Dai B, Kang M, Ann DK, Kung HJ, et al. Bi-directional regulation between tyrosine kinase Etk\/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem. 2004;279:50181\u20139.","journal-title":"J Biol Chem"},{"key":"8131_CR15","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1038\/emboj.2010.244","volume":"29","author":"JL Fox","year":"2010","unstructured":"Fox JL, Ismail F, Azad A, Ternette N, Leverrier S, Edelmann MJ, et al. Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J. 2010;29:3853\u201368.","journal-title":"EMBO J"},{"key":"8131_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.18632\/oncoscience.276","volume":"2","author":"JL Fox","year":"2015","unstructured":"Fox JL. Cancer chemoresistance and BAK. Oncoscience. 2015;2:932\u20133.","journal-title":"Oncoscience"},{"key":"8131_CR17","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1128\/MCB.21.14.4647-4655.2001","volume":"21","author":"I Rajantie","year":"2001","unstructured":"Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001;21:4647\u201355.","journal-title":"Mol Cell Biol"},{"key":"8131_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1039\/D0CB00033G","volume":"1","author":"JD Seixas","year":"2020","unstructured":"Seixas JD, Sousa BB, Marques MC, Guerreiro A, Traquete R, Rodrigues T, et al. Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors. RSC Chem Biol. 2020;1:251\u201362.","journal-title":"RSC Chem Biol"},{"key":"8131_CR19","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61:3891\u201398.","journal-title":"J Chem Inf Model"},{"key":"8131_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/15748928113089990043","volume":"8","author":"JS Jarboe","year":"2013","unstructured":"Jarboe JS, Dutta S, Velu SE, Willey CD. Mini-review: bmx kinase inhibitors for cancer therapy. Recent Pat Anticancer Drug Discov. 2013;8:228\u201338.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"8131_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1021\/cb4000629","volume":"8","author":"F Liu","year":"2013","unstructured":"Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, et al. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013;8:1423\u20138.","journal-title":"ACS Chem Biol"},{"key":"8131_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1021\/acs.jmedchem.6b01413","volume":"60","author":"X Liang","year":"2017","unstructured":"Liang X, Lv F, Wang B, Yu K, Wu H, Qi Z, et al. Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)p henyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med Chem. 2017;60:1793\u2013816.","journal-title":"Med Chem"},{"key":"8131_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.chembiol.2013.06.001","volume":"20","author":"DK Treiber","year":"2013","unstructured":"Treiber DK, Shah NP. Ins and outs of kinase DFG motifs. Chem Biol. 2013;20:745\u20136.","journal-title":"Chem Biol"},{"key":"8131_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1021\/acs.jmedchem.1c01186","volume":"65","author":"R Liu","year":"2022","unstructured":"Liu R, Zhan S, Che Y, Shen J. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases. J Med Chem. 2022;65:1525\u201335.","journal-title":"J Med Chem"},{"key":"8131_CR25","doi-asserted-by":"crossref","unstructured":"Chun KS, Kim DH, Surh YJ. Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance. Cells. 2021;30:10.","DOI":"10.3390\/cells10040758"},{"key":"8131_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"8131_CR27","doi-asserted-by":"crossref","unstructured":"Montoya S, Soong D, Nguyen N, Affer M, Munamarty SP, Taylor J. Targeted Therapies in Cancer: To Be or Not to Be, Selective. Biomedicines. 2021;01:9.","DOI":"10.3390\/biomedicines9111591"},{"key":"8131_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/2040620714539906","volume":"5","author":"A Aalipour","year":"2014","unstructured":"Aalipour A, Advani RH. Bruton\u2019s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014;5:121\u201333.","journal-title":"Ther Adv Hematol"},{"key":"8131_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological Toxicities of Bruton\u2019s Tyrosine Kinase Inhibitors. Am J Clin Dermatol. 2020;21:799\u2013812.","journal-title":"Am J Clin Dermatol"},{"key":"8131_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/cb500696t","volume":"10","author":"PM Ung","year":"2015","unstructured":"Ung PM, Schlessinger A. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. ACS Chem Biol. 2015;10:269\u201378.","journal-title":"ACS Chem Biol"},{"key":"8131_CR31","doi-asserted-by":"crossref","unstructured":"Huang F, Han X, Xiao X, Zhou J. Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development. Molecules. 2022;10:27.","DOI":"10.3390\/molecules27227728"},{"key":"8131_CR32","doi-asserted-by":"publisher","first-page":"109747","DOI":"10.1016\/j.cbi.2021.109747","volume":"351","author":"S Jiang","year":"2022","unstructured":"Jiang S, Jiang T, Huang H, Chen X, Li L, Wang Z, et al. CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway. Chem Biol Interact. 2022;351:109747.","journal-title":"Chem Biol Interact"},{"key":"8131_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1083\/jcb.144.5.903","volume":"144","author":"GJ Griffiths","year":"1999","unstructured":"Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. Journal cell Biol. 1999;144:903\u201314.","journal-title":"Journal cell Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08131-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:07:18Z","timestamp":1762787238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08131-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8131"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08131-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"813"}}